|
| Press Releases |
|
 |
|
| Thursday, June 25, 2020 |
|
|
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea |
| Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide"). more info >> |
|
| Wednesday, June 10, 2020 |
|
|
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa |
| Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel coronavirus infection in Africa, beginning with the activities described below. more info >> |
|
| Thursday, June 4, 2020 |
|
|
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons |
| Eisai Co., Ltd. announced today that the digital tool for self-assessment of brain performance (brain health) "NouKNOWTM", which Eisai has launched in Japan, is to be expanded in the fixed-rate membership beauty salon "Attina", which is operated by Youforio Co., Ltd. more info >> |
|
| Tuesday, June 2, 2020 |
|
|
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the U.S. on June 1, 2020. more info >> |
|
| Friday, May 29, 2020 |
|
|
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody |
| AbbVie GK and Eisai Co., Ltd. today announced an approval of partial changes in the marketing approval of HUMIRA (generic name: adalimumab [recombinant], hereafter "HUMIRA"), a fully human anti-TNFalpha monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (Q2W) regimen as a treatment option for patients with hidradenitis suppurativa (HS) after the first 4 weeks of treatment. more info >> |
|
|
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials |
| The two trials, Study 116/KEYNOTE-524 and Study 111/KEYNOTE-146, examined patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively. more info >> |
|
| Monday, May 18, 2020 |
|
|
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules |
| Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020. more info >> |
|
| Thursday, May 14, 2020 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate and eribulin mesylate will be given at the American Society of Clinical Oncology, from May 29 to 31, 2020. more info >> |
|
| Monday, April 27, 2020 |
|
|
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine |
| This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector. more info >> |
|
| Wednesday, April 1, 2020 |
|
|
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China |
| Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 23, 2024 20:42 HKT/SGT
|
|
|
First Quarterly Profit, High-Quality Platform Growth, NaaS Technology Accelerates Ecosystem Development
Nov 22, 2024 23:22 HKT/SGT
|
|
|
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Interim Results
Nov 22, 2024 19:56 HKT/SGT
|
|
|
Daeshin MC Co., Ltd. Unveils Its Clean Solutions Creating Pleasant Indoor Environments from Industrial Sites to Public Facilities 
Nov 22, 2024 11:00 HKT/SGT
|
|
|
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
|
|
|
Jacobson Pharma Announces FY2025 Interim Results
Nov 22, 2024 10:00 HKT/SGT
|
|
|
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
|
|
|
GMG Unveils SUPER G(R): A Game-Changing Graphene Solution for the Lithium-Ion Battery Industry
Nov 21, 2024 21:29 HKT/SGT
|
|
|
neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Nov 21, 2024 21:20 HKT/SGT
|
|
|
Experience the Power of Movement: Jin Pilates Brings Singapore's First Garuda Studio for Dynamic, Holistic Wellness
Nov 21, 2024 20:19 HKT/SGT
|
|
|
SGX-Listed Mooreast Appoints Norwegian Eirik Ellingsen as CEO to Drive Growth in Global Floating Offshore Wind Market
Nov 21, 2024 19:00 HKT/SGT
|
|
|
DesignInspire opens on December 5, with free admission for the public
Nov 21, 2024 17:54 HKT/SGT
|
|
|
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
|
|
|
Yahoo Finance Invest Asia 2024 - Disrupting Finance: Innovations Shaping The Future
Nov 21, 2024 14:14 HKT/SGT
|
|
|
TGL Presented by SoFi Names SYNLawn As Official Synthetic Surface Partner, Providing 31,000 Square Feet of Turf for SoFi Center's Tech-Infused Field of Play
Nov 21, 2024 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
